… our earlier-stage pipeline candidates, and to advance our Axiomer ® and Trident ™ RNA-editing technology platforms.” … through intravitreal injections in the eye. About Axiomer and Trident ProQR is pioneering a next-generation RNA … yield a new class of medicines for genetic diseases. Axiomer “Editing Oligonucleotides”, or EONs, mediate single …
… EST This presentation will highlight ProQR’s proprietary Axiomer ® platform, a fully owned and in house developed RNA … in the retina with oligonucleotide therapeutics. About Axiomer ® platform technology ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… and key opinion leaders and introduced next-generation Axiomer ® RNA technology platform. LEIDEN, the Netherlands, … trial in 2018. Beyond that, we are excited about the Axiomer ® platform technology we announced at our R&D day. … the event, the Company also introduced its next-generation Axiomer ® RNA technology platform, which has the potential to …
… to ProQR’s novel RNA editing platform technology called Axiomer LEIDEN, the Netherlands, May 09, 2017 (GLOBE … led to a novel proprietary RNA editing platform, called Axiomer, which in our view is the next step in RNA …